Phosphatidate phosphatase

Phosphatidate phosphatase (PAP) (EC 3.1.3.4) is a key regulatory enzyme in lipid metabolism, catalyzing the conversion of phosphatidate to diacylglycerol. The two substrates of PAP are phosphatidate and H₂O, and its two products are diacylglycerol and phosphate, as shown here.^[1]

a 1,2-diacylglycerol 3-phosphate + H₂O ${\displaystyle \rightleftharpoons }$ a 1,2-diacyl-sn-glycerol (DAG) + phosphate^[2]

The reverse reaction is catalyzed by the enzyme diacylglycerol kinase (DGK or DAGK), which replaces the hydroxyl group on diacylgylcerol with a phosphate from ATP, generating ADP in the process. While ATP is used by DGK in mammalian cells, yeast cells tend to use CTP as the high-energy phosphate donor instead.^[3] Mechanistically speaking, this has no effect on the overall reaction.

In yeast, the forward direction is ${\displaystyle {\ce {Mg^2+}}}$-dependent, while the reverse direction is ${\displaystyle {\ce {Ca^2+}}}$-dependent.^[3] PAP1, a cytosolic phosphatidate phosphatase found in the lung, is also ${\displaystyle {\ce {Mg^2+}}}$-dependent, but PAP2, a six-transmembrane-domain integral protein found in the plasma membrane, is not.^[4][5]

Reactants and products of the reaction catalyzed by the enzyme phosphatidate phosphatase, and thus also those of the reverse reaction, which is catalyzed by the enzyme diacylglycerol kinase.

Role in the regulation of lipid flux[]

PAP regulates lipid metabolism in several ways. In short, PAP is a key player in controlling the overall flux of triacylglycerols to phospholipids and vice versa, also exerting control through the generation and degradation of lipid-signaling molecules related to phosphatidate.^[4] When PAP is active, diacylglycerols formed by PAP can go on to form any of several products, including phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, and triacylglycerol.^[6] Phospholipids can be formed from diacylglycerol through reaction with activated alcohols, and triacylglycerols can be formed from DAG through reaction with fatty acyl CoA molecules. When PAP is inactive, DGK drives the reaction in reverse, allowing phosphatidate to accumulate as it brings down DAG levels. Phosphatidate can then be converted into an activated form, CDP-DAG, through the liberation of a pyrophosphate from a CTP molecule, or into cardiolipin. CDP-DAG is a principal precursor used by the body in phospholipid synthesis. Furthermore, because both phosphatidate and DAG function as secondary messengers, PAP is able to exert extensive and intricate control of lipid metabolism far beyond its local effect on phopshatidate and DAG concentrations and the resulting effect on the direction of lipid flux as outlined above.^[7]

Enzyme regulation[]

PAP is upregulated by CDP-diacylglycerol, phosphatidylinositol (formed from reaction of CDP-DAG with inositol), and cardiolipin. PAP is downregulated by sphingosine and dihydrosphingosine. This makes sense in the context of the discussion above. Namely, a build up of products that are formed from phosphatidate serves to upregulate PAP, the enzyme that consumes phosphatidate, thereby acting as a signal that phosphatidate is in abundance and causing its consumption. At the same time, a build up of products that are formed from DAG serves to downregulate PAP, the enzyme that forms DAG, thereby acting as a signal that DAG is in abundance and its production should be slowed.^[7]

Classification[]

PAP belongs to the family of enzymes known as hydrolases, and more specifically to the hydrolases that act on phosphoric monoester bonds. This enzyme participates in 4 metabolic pathways: glycerolipid, glycerophospholipid, ether lipid, and sphingolipid metabolism.

Nomenclature[]

The systematic name of this enzyme class is diacylglycerol-3-phosphate phosphohydrolase.^[8] Other names in common use include:

• phosphatidic acid phosphatase (PAP),
• 3-sn-phosphatidate phosphohydrolase,
• acid phosphatidyl phosphatase,
• phosphatidic acid phosphohydrolase,
• phosphatidate phosphohydrolase, and
• lipid phosphate phosphohydrolase (LPP).

Types[]

There are several different genes that code for phosphatidate phosphatases. They fall into one of two types (type I and type II), depending on their cellular localization and substrate specificity.^[9]

Type I[]

Type I phosphatidate phosphatases are soluble enzymes that can associate to membranes. They are found mainly in the cytosol and the nucleus. Encoded for by a group of genes named Lipin, they are substrate specific only to phosphatidate. There are speculated to be involved in the de novo synthesis of glycerolipids.

Each of the 3 Lipin proteins found in mammals—Lipin1, Lipin2, and Lipin3—has unique tissue expression motifs and distinct physiological functions.^[10]

Regulation[]

Regulation of mammalian Lipin PAP enzymes occurs at the transcriptional level. For example, Lipin1 is induced by glucocorticoids during adipocyte differentiation as well as in cells that are experiencing ER proliferation. Lipin2, on the other hand, is repressed during adipocyte differentiation.^[3]

Lipin is phosphorylated in response to insulin in skeletal muscle and adipocytes, linking the physiologic action of insulin to fat cell differentiation. Lipin phosphorylation is inhibited by treatment with rapamycin, suggesting that mTOR controls signal transduction feeding into lipin and may partially explain dyslipidemia resulting from rapamycin therapy.^[11]

Type II[]

Type II phosphatidate phosphatases are transmembrane enzymes found mainly in the plasma membrane. They can dephosphorylate other substrates besides phosphatidate, and therefore are also known as lipid phosphate phosphatases. Their main role is in lipid signaling and in phospholipid head-group remodeling.

One example of a type II phosphatidate phosphatase is PgpB (PDBe: 5jwy).^[12][13] PgpB is one of three integral membrane phosphatases in Escherichia coli that catalyzes the dephosphorylation of phosphatidylglycerol phosphate (PGP) to PG (phosphatidylglycerol).^[14] The other two are PgpA and PgpC. While all three catalyze the reaction from PGP to PG, their amino acid sequences are dissimilar and it is predicted that their active sites open to different sides of the cytoplasmic membrane. PG accounts for approximately 20% of the total membrane lipid composition in the inner membrane of bacteria. PgpB is competitively inhibited by phosphatidylethanolamine (PE), a phospholipid formed from DAG. This is therefore an example of negative feedback regulation. The enzyme active site contains a catalytic triad Asp-211, His-207, and His-163 that establishes a charge relay system. However, this catalytic triad is essential for the dephosphorylation of lysophosphatidic acid, phosphatidic acid, and sphingosine-1-phosphate, but is not essential in its entirety for the enzyme's native substrate, phosphatidylglycerol phosphate; His-207 alone is sufficient to hydrolyze PGP.^[14]

Dephosphorylation of phosphatidylglycerol phosphate (PGP) to form PG (phosphatidylglycerol). This reaction is catalyzed by PgpB, a bacterial integral membrane lipid phosphate phosphatase.

In the cartoon depiction of PgpB below, one can see its six transmembrane alpha helices, which are here shown horizontally. Of the three PGP phosphatases discussed above, PgpB is the only to have multiple transmembrane alpha helices.^[14]

PgpB (PDBe: 5jwy) cartoon with ribbons. Made in MacPyMOL.

Genes[]

Human genes that encode phosphatidate phosphatases include:

• PPAP2A (LPP1) – phosphatidic acid phosphatase type 2A
• PPAP2B (LPP3) – phosphatidic acid phosphatase type 2B
• PPAP2C (LPP2) – phosphatidic acid phosphatase type 2C
• PPAPDC1A (PPC1A) – phosphatidic acid phosphatase type 2 domain containing 1A
• (PPC1B) – phosphatidic acid phosphatase type 2 domain containing 1B
• – phosphatidic acid phosphatase type 2 domain containing 2
• – phosphatidic acid phosphatase type 2 domain containing 3
• – lipid phosphate phosphatase-related protein type 2
• – lipid phosphate phosphatase-related protein type 3
• – lipid phosphate phosphatase-related protein type 4
• LPIN1 – lipin 1^[15][16]
• – lipin 2^[16]
• – lipin 3^[16]

Pathology[]

Lipin-1 deficiency in mice results in lipodystrophy, insulin resistance, and neuropathy. In humans, variations in Lipin-1 expression levels can result in insulin sensitivity, hypertension, and risk for metabolic syndrome. Serious mutations in Lipin-2 lead to an inflammatory disorder in humans.^[10]

References[]